News & Updates
Filter by Specialty:
Adjuvant sorafenib after RFA boosts survival in recurrent hepatocellular carcinoma
The use of sorafenib as an adjuvant therapy after radiofrequency ablation (RFA) appears to improve survival outcomes in patients with recurrent hepatocellular carcinoma who underwent hepatectomy, according to a study.
Adjuvant sorafenib after RFA boosts survival in recurrent hepatocellular carcinoma
27 Aug 2022
Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
Use of pimavanserin appears to be more effective than atypical antipsychotic agents in reducing mortality among Parkinson’s disease patients during the first 180 days of treatment, reveals a study. However, such benefit is seen only in community-dwelling patients and not in nursing home residents.
Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
26 Aug 2022
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
25 Aug 2022
Use of antipsychotics, but not opioids, drops in nursing home residents with dementia
Prescription of antipsychotic and anxiolytic medications has decreased among residents with dementia in Veterans Health Administration (VHA) nursing homes, but overall prescribing of other psychotropic and opioid agents has increased, reports a study.
Use of antipsychotics, but not opioids, drops in nursing home residents with dementia
25 Aug 2022
Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.
Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
24 Aug 2022
OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.